立体定向体部放疗再照射治疗局部复发直肠癌的疗效与毒性
本研究基于前瞻性登记数据,纳入30例既往接受过盆腔放疗、现因不可手术的局部复发直肠癌接受SBRT(30 Gy/5次)的患者。中位随访24.5个月,1年局部控制率为84.9%,2年局部控制率为69%,中位总生存期为28.3个月,未出现>G2急性毒性,仅1例发生晚期G3毒性,3个月时患者报告的生活质量评分改善。
要点
- SBRT再照射30 Gy/5次对小的盆腔复发灶局部控制率高。
- 急性毒性均≤G2,晚期仅1例G3毒性,安全性可接受。
核心结论
- 对于直肠癌小体积盆腔复发灶,30 Gy/5次SBRT再照射耐受良好,在高局部控制率与有限毒性之间取得良好平衡。
研究设计与样本
- 从前瞻性登记数据库中筛选4年内不可手术、盆腔复发灶≤3处且距前次盆腔放疗>6个月的患者。
- SBRT剂量为30 Gy分5次,每日或隔日照射,采用累积危及器官剂量约束。
- 共纳入30例患者、35个靶区,中位肿瘤体积14.3 cm3。
- 主要终点为局部控制,次要终点包括无进展生存、总生存、毒性和EQ-VAS生活质量评分。
主要发现
- 中位随访24.5个月(四分位距17.8-28.8)。
- 1年局部控制率为84.9%(95%CI 70.6-99),2年局部控制率为69%(95%CI 51.8-91.9)。
- 中位无进展生存期为12.1个月(95%CI 8.6-17.66),中位总生存期为28.3个月(95%CI 17.88-39.5)。
- 无患者发生>G2急性毒性,仅1例发生晚期G3毒性。
关键数值与推荐
- 入组条件:不可手术、盆腔复发灶≤3处、距前次盆腔放疗>6个月。
- SBRT处方剂量为30 Gy分5次。
- 27/30例(90%)既往接受45-50.4 Gy分25/28次,10%接受其他处方。
- 所有患者均完成计划的再照射SBRT剂量。
临床怎么用
- 对于既往盆腔放疗后小体积局部复发直肠癌,可考虑30 Gy/5次SBRT再照射。
- 治疗时需采用累积危及器官剂量约束以控制毒性。
- 再照射后应关注患者报告的生活质量变化。
局限性
- 样本量较小(30例患者、35个靶区)。
- 来自单中心前瞻性登记数据,随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic body radiation therapy (SBRT) has emerged as a potential therapeutic option for locally recurrent rectal cancer (LRRC) but contemporaneous clinical data are limited. We aimed to evaluate the local control, toxicity, and survival outcomes in a cohort of patients previously treated with neoadjuvant pelvic radiation therapy for nonmetastatic locally recurrent rectal cancer, now treated with SBRT. METHODS AND MATERIALS: Inoperable rectal cancer patients with ≤3 sites of pelvic recurrence and >6 months since prior pelvic radiation therapy were identified from a prospective registry over 4 years. SBRT dose was 30 Gy in 5 fractions, daily or alternate days, using cumulative organ at risk dose constraints. Primary outcome was local control (LC). Secondary outcomes were progression free survival, overall survival, toxicity, and patient reported quality of life scores using the EQ visual analog scale (EQ-VAS) tool. RESULTS: Thirty patients (35 targets) were included. Median gross tumor volume size was 14.3 cm3. In addition, 27 of 30 (90%) previously received 45 to 50.4 Gy in 25 of 28 fractions, with 10% receiving an alternative prescription. All patients received the planned reirradiation SBRT dose. The median follow-up was 24.5 months (interquartile range, 17.8-28.8). The 1-year LC was 84.9% (95% confidence interval [CI], 70.6-99) and a 2-year LC was 69% (95% CI, 51.8-91.9). The median progression free survival was 12.1 months (95% CI, 8.6-17.66), and median overall survival was 28.3 months (95% CI, 17.88-39.5 months). No patient experienced >G2 acute toxicity and only 1 patient experienced late G3 toxicity. Patient-reported QoL outcomes were improved at 3 months after SBRT (Δ EQ-VAS, +10 points, Wilcoxon signed-rank, P = .009). CONCLUSIONS: Our study demonstrates that, for small volume pelvic disease relapses from rectal cancer, reirradiation with 30 Gy in 5 fractions is well tolerated and achieves an excellent balance between high local control rates with limited toxicity.
引用
- Smith T, O'Cathail SM, Silverman S, et al. Stereotactic Body Radiation Therapy Reirradiation for Locally Recurrent Rectal Cancer: Outcomes and Toxicity. Adv Radiat Oncol. 2020. PMID: 33305093. doi:10.1016/j.adro.2020.07.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。